Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$344.52
pos +2.79
+0.82%
Today's Range: 343.02 - 349.00 | BIIB Avg Daily Volume: 1,158,300
Last Update: 07/30/14 - 4:00 PM EDT
Volume: 1,303,122
YTD Performance: 22.23%
Open: $344.45
Previous Close: $341.73
52 Week Range: $203.55 - $358.89
Oustanding Shares: 236,144,705
Market Cap: 79,436,717,315
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 13 13 13
Moderate Buy 1 0 0 0
Hold 5 5 5 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.69 1.56 1.56 1.63
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 37.42
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
37.42 37.40 28.94
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
17.50% 58.24% 235.46%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.70 0.97 0.25
Earnings for BIIB:
EBITDA 1.90B
Revenue 5.81B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $3.53 $3.66 $13.13 $16.77
Number of Analysts 1 1 1 1
High Estimate $3.53 $3.66 $13.13 $16.77
Low Estimate $3.53 $3.66 $13.13 $16.77
Prior Year $2.34 $2.33 $8.93 $13.13
Growth Rate (Year over Year) 50.85% 57.08% 47.03% 27.72%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Jul 24, 2014 | 8:10 AM EDT
BIIB price target raised from $380 to $410, Jefferies said. Buy rating. Company beat estimates due to strong Tysabri and Tecfidera...
Bullish
Jul 24, 2014 | 7:48 AM EDT
Shares of BIIB now seen reaching $425, according to Credit Suisse. Estimates also increased, as management guided to higher Tecfidera g...
In theory there should be plenty of shorting opportunities.
Too many people are willing to park cash in Microsoft or Apple.
McDonald's and GlaxoSmithKline are fighting against major turns of the tide.
This may be one of only two technical buying opportunities in 2014. 
Update
Jun 12, 2014 | 7:11 AM EDT
BIIB - Biogen Idec Inc. Annual Shareholder Meeting - 9AM
Become more aggressive about the real valuations of companies.
Shorts take much more homework than longs.
Bullish
May 29, 2014 | 7:45 AM EDT
BIIB was upgraded from Neutral to Overweight, JP Morgan said. $375 price target. Company has multiple, mid-stage pipeline opportunities...

Columnist Conversations

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
Market gets hit from impact of sanctions against Russia for second day in row but manages to rally a bit to en...
We took out some of the high end of support, but I'm still looking at this symmetrical pullback for entries on...
going into trading today roughly 37 million shares of X (US Steel) was held short.today big X has traded 27 mi...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.